Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy.

Immunotherapy - 1 Sept 2017

McGinnis Gwendolyn J, Raber Jacob

Abstract excerpt

Following cancer treatment, patients often report behavioral and cognitive changes. Novel cancer immunotherapeutics have the potential to produce sustained cancer survivorship, meaning patients will live longer with the side effects of treatment. Given the role of inflammatory pathways in mediating behavioral and cognitive impairments seen in cancer, we aim in this review to discuss emerging evidence for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Behavior
Share to Central Nervous System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cognition

Share to Drug Evaluation, Preclinical

Share to Molecular Targeted Therapy

Share to Neurotoxicity Syndromes

Share to Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 29338610
DOI: 10.2217/imt-2017-0056
PMCID: PMC6161123

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy.PMID 29338610Read ↗

Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.Semantic proximity Read ↗

Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.Semantic proximity Read ↗

Characterization of tumour interactions with the immune system in an autochthonous mouse model of glioblastomaSemantic proximity Read ↗

Differential effects of PD-1 and PD-L1 immune checkpoint inhibition on cognition and anxiety-like behavior through γδT cells and tumor–dependent neuroinflammationSemantic proximity Read ↗

Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approachSemantic proximity Read ↗

Adverse events induced by immune checkpoint inhibitors.Semantic proximity Read ↗

Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockadeSemantic proximity Read ↗

Immunotherapy-related cognitive impairment after CAR T cell therapy in miceSemantic proximity Read ↗

Radiation with STAT3 Blockade Triggers Dendritic Cell–T cell Interactions in the Glioma Microenvironment and Therapeutic EfficacySemantic proximity Read ↗

Tumor cell-derived spermidine promotes a pro-tumorigenic immune microenvironment in glioblastoma via CD8+ T cell inhibitionSemantic proximity Read ↗

Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.